Bluefin Capital Management’s AstraZeneca AZN Stock Holding History

Bluefin Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-5,000	Closed	-$1K	–	940
2021 Q3	$1K	Hold	5,000	–	–	﹤0.01%	727
2021 Q2	$3K	Buy	+5,000	New	+$549K	﹤0.01%	640
2015 Q1	–	Sell	-636,400	Closed	-$830K	–	429
2014 Q4	$830K	Sell	636,400 -195,400	-23%	-$14M	0.05%	285
2014 Q3	$1.87M	Buy	831,800 +827,990	+21,732%	+$60.6M	0.1%	197
2014 Q2	$600K	Buy	+3,810	New	+$275K	0.03%	397

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

Bluefin Capital Management's AZN Position: Q1 2022 in Review

Bluefin Capital Management sold out of AstraZeneca (AZN) in Q1 2022, closing a stake of 7,231 shares — an estimated $842K sold.

Bluefin Capital Management first reported a position in AZN in Q1 2014 and held it in 16 quarters. The position peaked at $31.5M in Q3 2014. 982 funds tracked by Wall St. Rank hold AZN as of Q1 2022.

Bluefin Capital Management reported no remaining AstraZeneca position as of Q1 2022 after selling out during the quarter.
Bluefin Capital Management sold 7,231 AstraZeneca shares in Q1 2022, an estimated $842K.
Bluefin Capital Management first reported a position in AstraZeneca in Q1 2014 and held it in 16 quarters.
Bluefin Capital Management's AstraZeneca position peaked at $31.5M in Q3 2014.
982 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2022.

Based on Bluefin Capital Management's 13F filing for Q1 2022, filed 16 May 2022.